No 6 (2019)
- Year: 2019
- Articles: 14
- URL: https://remedium-journal.ru/journal/issue/view/103
Articles
Klinicheskoe issledovanie rossiyskogo protivoopukholevogo preparata
Abstract
Минздрав РФ выдал разрешение на клиническое исследование безопасности и предварительной эффективности российского экспериментального противоопухолевого препарата алофаниб. В исследовании, которое пройдет в клиниках Москвы, Санкт-Петербурга, Омска и Ростова-на-Дону, примут участие больные метастатическим раком желудка, не ответившие на стандартные методы лечения. Алофаниб - первый аллостерический ингибитор рецептора фактора роста фибробластов FGFR2. Этот рецептор, участвующий в запуске процесса клеточного деления, роста и распространения опухолей, имеется у клеток многих злокачественных новообразований. В отличие от разрабатываемых в настоящее время внутриклеточных ингибиторов FGFR2, алофаниб блокирует внеклеточную часть рецептора, которая не меняет свою структуру вследствие мутаций. Таким образом, эффективность терапии не зависит от появления тех или иных изоформ FGRF2. Данный подход к терапии онкологических заболеваний признан инновационным и запатентован компанией «Русфармтех» в России, странах ЕАЭС, США, Европейском союзе, Японии и Китае.
REMEDIUM. 2019;(6):4-5
Medical representative. Reset
Abstract
This article is prepared after considering the results of IQVIA survey and is devoted to an analysis of the changes that came along with new technologies and affected the pharmaceutical industry. The author identified the main trends in the development of Salesforce in European countries and showed the key factors for reducing FTE. The article also provided the results of the survey of the professional medical community about their perceptions of pharmaceutical promotion: the relevance of the information and how it is provided. Based on the research, IQVIA experts identified the main areas for improving the skills of medical representatives and the conditions for ensuring the success of MSL. A comparative analysis of visits with digital support and the "traditional" visits showed the relevance of the introduction of digital technologies as a working tool in the daily activities of representatives. Therefore, the commercial model, which integrates and involves all available digital and traditional channels, and which team includes not only Salesforce, but also other divisions, is deemed to be the most successful and efficient.
REMEDIUM. 2019;(6):6-12
Structural changes and import substitution processes in the VZN segment in 2008-2018
Abstract
The paper deals with the analysis of the dynamics and structure changes in the segment of VZN program (the state reimbursement program for very expensive medicines' provision for the treatment of diseases included into the approved list). During the program implementation period from 2008 to 2018 the value of the state purchases has grown 1.5 times and reached 50 bln rubles in the contract prices. The structure of purchases with respect to treatment of different diseases remained stable enough during the entire period of the program implementation.
REMEDIUM. 2019;(6):14-19
Pharmacy drug market in russia: results of the first half of 2019
Abstract
The Russian pharmaceutical market has been demonstrating positive steady growth in terms of value for quite a long time, but its pace has slowed down significantly in recent years. Traditionally, the pharmacy sector remains the main driver of changes in the market. You can understand how the situation developed in individual segments of the pharmaceutical pharma market in the first quarter of 2019 by reviewing the key market indicators in this period.
REMEDIUM. 2019;(6):20-24
«Reshit' problemu defitsita zheleza segodnya vpolne vozmozhno». Interv'yu s Viktorom Radzinskim
Abstract
Железодефицитная анемия (ЖДА), на долю которой приходится до 80-90% всех анемий, остается серьезным вызовом для практических врачей разной специализации. О причинах, лежащих в основе этого заболевания, и мерах, необходимых для решения проблемы, мы решили поговорить с Виктором РАДЗИНСКИМ, заслуженным деятелем науки РФ, членом-корреспондентом РАН, заведующим кафедрой акушерства и гинекологии с курсом перинатологии Медицинского института РУДН, вице-президентом Российского общества акушеров-гинекологов, президентом Междисциплинарной ассоциации специалистов репродуктивной медицины (МАРС), д.м.н., профессором. В этом году В.Е. Радзинский стал лауреатом общенациональной премии «Профессор года».
REMEDIUM. 2019;(6):25-26
Iron argument in the struggle for health
Abstract
Iron deficiency anemia (IDA) is at the top of the list of 38 most common human diseases [1]. According to WHO report in 2015, every third woman of reproductive age and every second pregnant woman has a severe iron deficiency [2]. Therefore, the search for optimal approaches to the treatment of IDA remains one of the urgent tasks of health care.
REMEDIUM. 2019;(6):27-29
Global pharmaceutical market: key trends
Abstract
According to the expert forecast, the global pharmaceutical market will continue to grow in the coming years, but its growth is likely to slow down slightly, reaching about 4--5% annually. The increase in market volumes will be due both to the actual dynamics of the segments that have been already formed, and largely to the growth in sales of innovative medicinal products (MP) [1]. This article presents an overview of key trends in the global pharmaceutical market.
REMEDIUM. 2019;(6):30-32
The use of information technology in pharmaceutical consulting
Abstract
The article presents a software program for standardization and optimization of pharmaceutical consulting on a specific disease in the pharmacies. It was developed using Visual Studio Code built on Electron platform and JavaScript language. The structure and logical sequence of the software was based on the previously developed algorithm for pharmaceutical consulting of pharmacy visitors in choosing medicines for the treatment and prevention of lower extremity varicose vein disease (without ulcers and inflammations). The software program can be used to increase the level of information and communication services in the retail segment of the pharmaceutical market.
REMEDIUM. 2019;(6):34-37
Monthly review: production, investment, finance
Abstract
Performance analysis of industry enterprises is conducted using the national statistics reports: Form No. P-1, term (monthly), Form No. P-2 Information on Investments in Non-Financial Assets (quarterly), Form No. P-3 Information on Company Financial Status (monthly).
REMEDIUM. 2019;(6):40-50
Quaterly overview of the medical device market: current state and prospects of development of the russian suture filament market
Abstract
The market analysis has been conducted on the basis of the data on state purchases of suture filaments, and the export-import transaction database of the official customs statistics.
REMEDIUM. 2019;(6):51-56
Monthly review: business activity of industry enterprises
Abstract
The rating was carried out using the national accounting statements of top 150 industry enterprises.
REMEDIUM. 2019;(6):57-60
Quarterly judicial review pertaining to the production and circulation of medical products for February - April 2019
Abstract
The monthly review provides an analysis of court practice pertaining to the production and circulation of medical products to help industry specialists avoid mistakes in solving similar problems.
REMEDIUM. 2019;(6):61-64
Umnye tekhnologii na sluzhbe zdravookhraneniya
Abstract
Одним из знаковых событий июня стало проведение X Форума инновационных технологий InfoSpace, собравшего на своей площадке представителей законодательной и исполнительной власти, отраслевых ассоциаций и общественных организаций, а также руководителей производственных предприятий, ученых и экспертов рынка.
REMEDIUM. 2019;(6):66-67
Pokazateli vedushchikh mirovykh i otechestvennykh proizvoditeley i distrib'yuterov
Abstract
По данным Росстата, индекс физического объема в апреле по крупным, средним и малым организациям по отношению к предыдущему месяцу по кодам ОКВЭД2 составил: 21 «Производство лекарственных средств и материалов, применяемых в медицинских целях» - 108,6%. 32.5 «Производство медицинских инструментов и оборудования» - в данном отчетном периоде определился на уровне 115,6%. • 26.6 «Производство облучающего и электротерапевтического оборудования, применяемого ^ в медицинских целях» -120,1%.
REMEDIUM. 2019;(6):68-72